Vanguard Asset Management
TRVI icon

Vanguard Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Vanguard Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
72,296
+19,042
+36% +$277K ﹤0.01% 1742
2026
Q1 		$635K Buy
+53,254
New +$596K ﹤0.01% 1985

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Asset Management's TRVI Position: Q2 2026 in Review

Vanguard Asset Management increased its Trevi Therapeutics (TRVI) stake by 36% in Q2 2026, buying an estimated $277K and bringing the position to 72,296 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Vanguard Asset Management first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Vanguard Asset Management held 72,296 shares of Trevi Therapeutics worth $1.35M as of Q2 2026.
  • Vanguard Asset Management bought 19,042 Trevi Therapeutics shares in Q2 2026, an estimated $277K.
  • Trevi Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1742 holding.
  • Vanguard Asset Management first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.